Evaluating the activity of temsirolimus in neuroendocrine cancer [1]

British Journal of Cancer

Volumn 96, Issue 1, 2007, Pages 177-

  O'Donnell, P H ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; GEFITINIB; OCTREOTIDE; SUNITINIB; TEMSIROLIMUS;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG RESPONSE; DRUG SCREENING; HUMAN; LETTER; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; DISEASE PROGRESSION; HUMANS; NEUROENDOCRINE TUMORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 33846202562     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603513     Document Type: Letter

References (5)

1. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B, International Lanreotide Interferon Alfa Study Group (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21(14): 2689-2696
2. Michaelis LC, Ratain MJ (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6(5): 409-414
3. Oberg K (2002) Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 14(1): 38-45
4. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16): 2505-2512
5. Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF (2000) Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 11: 1127-1130